Point-of-Care Surface Plasmon Resonance Biosensor for Stroke Biomarkers NT-proBNP and S100ß Using a Functionalized Gold Chip with Specific Antibody.

Surface-plasmon-resonance (SPR) is a quantum-electromagnetic phenomenon arising from the interaction of light with free electrons at a metal-dielectric interface. At a specific angle/wavelength of light, the photon's energy is transferred to excite the oscillation of the free electrons on the surface. A change in the refractive-index (RI) may occur, which is influenced by the analyte concentration in the medium in close contact with the metal surface. SPR has been widely used for the detection of gaseous, liquid, or solid samples. In this study, a functionalized specific SPR chip was designed and used in a novel point-of-care SPR module (PhotonicSys SPR H5) for the detection of the stroke biomarkers NT-proBNP and S100ß. These biomarkers have proven to be good for stroke diagnosis, with sensitivity and specificity of >85%. Specific detection was done by binding a biomolecular-recognizing antibody onto the Au SPR-chip. Detection was tested in water and plasma samples. NT-proBNP and S100ß were detected in a range of concentrations for stroke, from 0.1 ng/mL to 10 ng/mL. The RI of the blank plasma samples was 1.362412, and the lowest concentration tested for both biomarkers showed a prominent shift in the RI signal (0.25 ng/mL NT-proBNP (1.364215) and S100ß (1.364024)). The sensor demonstrated a clinically relevant limit-of-detection of less than ng/mL.

Improving sensitivity of a miniaturized label-free electrochemical biosensor using zigzag electrodes.

Cardiovascular disease (CVD) is a leading cause of death among chronic diseases worldwide. Therefore, it is important to be able to detect CVD biomarkers early so that patients can be diagnosed properly and begin treatment as soon as possible. To detect biomarkers more conveniently, point-of-care (PoC) biosensors, which are easy to use and are of low cost, are becoming even more necessary. This paper focuses on developing a label-free electrochemical biosensor with high sensitivity for PoC applications to detect CVD biomarkers such as S100 beta proteins and C-reactive proteins (CRP). To meet the requirements of a PoC application and to improve the measurement sensitivity for detection purposes, a three-electrode configuration was miniaturized and fitted onto a biochip. Computer simulation of an electrolyte current density was used to investigate several potential effective possibilities. It was found that an electrolyte current density at an edge tip structure near the working electrode (WE) and counter electrode (CE) was higher than at other locations. A zigzag structure was then designed at the edge near the WE and CE positions. With this design, we can obtain a higher total electrolyte current. This newly-designed biochip was then used to measure the electrochemical feature. It was found that the measurement efficiency was also improved using this newly designed biochip.

Functional expression, characterization, and application of human S100B.

The EF-hand calcium-binding protein S100B presents a wide range of biological activities and functions. This binding protein is involved in various human diseases, including cancer, brain trauma and ischemia, neuro-degenerative disease (Alzheimer's disease), and psychiatric disorders. In this study, we prepared human S100B protein and its monoclonal antibodies. Human S100B protein was expressed in Escherichia coli, successfully purified by diethylaminoethyl cellulose anion-exchange chromatography, and then identified by western blot analysis. Monoclonal antibodies (mAbs) were produced by the standard hybridoma method and validated by enzyme-linked immunosorbent assay and western blot analysis. The prepared human S100B protein and its mAbs demonstrated potential biological activities. The KD of one mAb is approximately 4.72x10-8 mol/l, and its cross reactivity is low with human S100A4, mouse S100A4, and human S100A1. Recombinant Soluble S100B can promote the migration and invasion of HeLa cells. The expression of S100B protein in tumor tissues can be detected effectively by using the prepared monoclonal antibodies. Increasing concentration of the anti-human S100B mAbs showed a reduced expression of the S100B protein. Subsequently, the expression of p53 increased significantly (P<0.05) in A375 cells. A significant increase in apoptosis in A375 cells was observed with increasing S100B mAb concentration. Results showed that our prepared S100B mAbs were suitable for detecting S100B expression in human tissues, furnishing promising tools for further functional investigation and clinical applications.